Here is a fact about BodyBio that is either charming or slightly alarming, depending on your relationship with FDA-registered facilities: the company's first product, an electrolyte concentrate called e-lyte, was reportedly mixed by its founder in his bathtub. This was 1998. The founder was Ed Kane, a biochemist, and the reason he was mixing electrolytes in a bathtub was that he had been unable to find anyone who could tell him why he felt terrible.
Most supplement companies are built the normal way, which is to say they start with a marketing insight - people want more energy, or better sleep, or a flatter stomach - and then reverse-engineer a pill to sell against it. BodyBio was built backward. It started with a diagnostic problem, then a diagnostic tool, and only arrived at supplements because the data kept pointing there.
First, the blood test
In the early 1990s, Kane, working with Patricia Kane, PhD, developed one of the first computerized systems that linked a person's blood chemistry and red-blood-cell fatty acids to specific nutritional deficiencies. They called it the BodyBio Biomedical Report. The pitch was unglamorous and, for the time, a little heretical: instead of treating symptoms, look at the raw biochemistry of the cell and figure out what it is missing.
This was functional medicine before functional medicine had a marketing budget. Through the 1990s and 2000s, BodyBio became a training hub - running seminars, mentoring practitioners, teaching doctors to read the reports. The company was, in effect, a small evidence factory. And the reports kept surfacing the same deficiencies over and over.
Then, the pivot
If you run enough blood tests and keep seeing the same missing nutrients, eventually someone points out that you could just make the missing nutrients. So Kane pivoted from diagnostics to manufacturing. The thesis he landed on is the one BodyBio still repeats today, and it fits on an index card: if you want to heal the body, you have to start with the cell.
The molecule that carries most of the weight here is phosphatidylcholine - a phospholipid that is a primary structural component of every cell membrane you own. BodyBio's flagship, BodyBio PC, is a liposomal phospholipid complex designed to repair and restore those membranes. It is not an especially sexy product to explain at a dinner party. It is, however, foundational biology, which is roughly the entire brand.
The boring moat
BodyBio did something else unusual: it sold to doctors first. Its products moved through a network of healthcare practitioners - now more than 35,000 of them - long before the company chased a consumer audience on Instagram. Practitioner trust is slower and harder to build than a viral ad, but it is a moat a competitor cannot simply outspend.
The company also owns its factory. In an industry that outsources manufacturing the way most people outsource laundry, BodyBio makes its products in-house in Millville. The payoff is traceability - the ability to say, with a straight face, exactly what is in the bottle and where it came from.
Today the company is run by Kane's grandchildren, Jess and Brad Berman, the third generation to hold the same index card. Ed Kane has since passed away, but the thesis outlived him, which is the rare and slightly moving thing that happens when the people who inherit a business actually understand its science. The numbers are modest by venture standards - roughly $14 million in revenue, about 58 employees, a single $670,000 seed round in 2018 - and that appears to be exactly the point. This is a company optimizing for longevity, not for a liquidity event. Fittingly, for a company that sells cellular repair.